BIT’s 9th Annual World Congress of Vaccine-2017
About WCV-2017

Following on the successful organizing of WCV-2016, we are pleased to announce the next WCV conference will be held during March 29-31, 2017 in Beijing, China. With the theme of “New Technologies, New Vaccines”, we will once again offer professionals in the field of vaccine a multidisciplinary informative platform.
WCV-2017 contributes to provide a unique platform which will bring together thought leaders from pharmaceutical, biotech companies, consultants, regulatory authorities and academics, to present the latest research results, ideas, developments, applications and business prospects in Vaccine Research and Technologies, Vaccine Drugs, and Production, Vaccine Market Trend & Policy, etc.

Highlights of the WCV-2017
  • 500+ Attendees Coming from All over the World to Exchange Ideas, Build New Networks, and Foster Friendships
  • 200+ Oral Presentations Covering the Hot Topics and Cutting-edge Technology in the Field of Antibody
  • 80+ Exhibitors and 30+ Posters Showcasing the Emerging New Products and Technologies
  • Social Activities and Networking, Field Trip and Tech-tour, Build Partnerships, Find Huge Opportunities and Markets for Your Business over the World
  • Opportunities to Visit Beijing Natural and Cultural Landscape
Renowned Speakers of WCV-2017

Dr. Xiao Donglou, Deputy Director General, Bureau of Disease Prevention and Control, Ministry of Health, China

Dr. Kelly T. McKee, Vice President, Chief Medical and Scientific Officer, Quintiles Transnational Corporation, USA

Dr. Madi R. Madiyalakan, CEO, Quest PharmaTech Inc.

Dr. Duccio Medini, Senior Director, GSK, Belgium

Dr. Mingde Xia, Senior Director, Johnson & Johnson Innovation, USA

Dr. Weikang Tao, Vice President and CEO of R&D Center, Jiangsu Henrui Medicine Co., Ltd., China

Dr. Daming Zhu, Head of Quality Control Unit, NIAID/NIH, USA

Dr. Weining Meng, International Regulatory Affairs Director, Sinovac Biotech Co. Ltd., China

Michael Vajdy, Co-founder, Principal and CSO, EpitoGenesis, Inc., USA

Dr. Sina Bavari, Science Director, US Army Medical Research Institute of Infectious Diseases, USA

Dr. Robert Rees, Professor, Nottingham Trent University, UK


Dr. Rainer Henning, CEO, Viravaxx GmbH, Austria

Dr. Tom H Jin, Senior Scientist, IDT Biologika, USA


Dr. Jung Sun Yum , Executive Director, CHA Vaccine Institute, Korea

Dr. Ming-Chung Kan, Founder, Vaxsia, Taiwan

Dr. Narcisa Mesaros, Clinical and Epidemiology R&D Project Leader, GSK, Belgium

Dr. Ali A. Mohammadi, President, Global Health and Security Consultants, Switzerland

Dr. Tong-Ming Fu, SeniorInvestigator, Merck Research Laboratories, USA

Dr. Viliam Pavliak, Head, International Vaccine Institute, Korea

Dr. Luis H. Martin, CEO, Pan-Provincial Vaccine Enterprise Inc., Canada

Dr. Robert H. Hall, Programs Officer, National Institute of Allergy and Infectious Diseases, USA

Dr. Yuri Vasiliev, Deputry Director for Science, St. Petersburg Research Institute for Vaccines and Sera, Russia

Dr. Kutub Mahmood, Scientific Director, Vaccine Development Global Program, PATH, USA

Dr. Yingxia Wen, Director, Seqirus, USA

Ms. Molly (Miao) Zhang, Project Coordinator, Aeras, China

Dr. Maurizio Barbeschi, Scientist, World Health Organization, Switzerland

Dr. Peter F. Billingsley, Vice President, Sanaria Inc., USA

Dr. Zakir Murtaza, COO/Chief Scientist, Applied Biomedical LLC, USA

Dr. Robert Menard, Group Leader, Institut Pasteur, France

Dr. Armando Zuniga, CSO, Virometix AG, Switzerland

Dr. Geert. C. Mudde, Founder and CSO, OncoQR ML GmbH, Austria

Dr. Bernard Vallat, Director, World Organisation for Animal Health, France

Dr. Devender Sandhu, Director, Providence Healthcare Foundation, USA

Dr. Artem Metlin, Deputy Director, Federal Centre for Animal Health, Russia

Dr. Shou-Bai Chao, Sr. Vice President, MedImmune, USA

Dr. Hubert C. Chen, Chief Medical Officer, Pfenex, USA

Dr. Kevin Mugur Galalae, Founder and Director, Center of Global Consciousness, Canada

Dr. Cristina Masuet-Aumatell, Associate Professor, University of Barcelona, Spain

Dr. Kokouvi Kassegne, National Institute of Parasitic Diseases, China CDC, China

Dr. Stéphanie McArdle, Senior Research Scientist in Tumour Immunology, Nottingham Trent University, UK

Dr. Michel Klein, CSO, BravoVax ,China

Dr. Gustavo A. Echenique, Head of Infectious Diseases, Tropical and Infectious Diseases Unit “Nuestra Señora del Rosario” Clinic, Argentina

Dr. Reinhard Zeidler, Professor, Ludwig Maximilians University, Germany

Dr. Tania Fernandez, Founder & CEO, DreamCatcher Ventures, USA

Dr. Tadeusz Stefaniak, Professor, Wroclaw University of Environmental and Life Sciences, Poland

William J. Kelly

William J. Kelly, Professor, Villanova University, USA

Dr. Andrew A. Potter, Director, University Of Saskatchewan, Canada

Program Layout
Cluster 1: Main Conference
Part One: Opening Ceremony Part Two: Keynote Forum
Cluster 2: Scientific Program
Pepeline 1: Vaccine R & D and New Technologies Pepeline 2: Human Vaccines for Major Infectious Diseases
Pepeline 3: Human Vaccines for Non-infectious Diseases Pepeline 4: Veterinary Vaccines
Pepeline 5: Vaccines Production and Manufacturing Pepeline 6: Vaccine Business / Safety / Regulatory / Legal Subjects
Cluster 3: Satellite Meeting
Pepeline 7: Blood Products Seminar
Cluster 4: Workshop and Training Course

• Industrial Sponsored Symposia  
• Matchmaking and Biopartnering
• Round Table Discussion
• Training Course

Cluster 5: Posters and EXPO
WCV-2017 will provide an ideal platform to showcase your new technologies and products in China. It is developed to maximize exposure of exhibitors, with coffee breaks and poster sessions for delegates taking place in the exhibition area.
Why Reserve a Booth at WCV-2017
  • Exposure Your New Products, Technology, Innovations and Latest Development to Visitors
  • Explore Business Opportunities in China and Beyond
  • Interaction with Visitors Face-to-Face, Exchanging Conversation and Sharing Information
  • Spotlight Your Technology and Its Commercial Application Promote Business
  • Take Advantage of the Targeted Audience at the Conference and Network in the Hall
  • Highlight your Impact and Influence
  • Increased Visibility and Name Recognition
  • Access to Competitive Intelligence
Cluster 6: Sponsorship
WCV-2017 is one of the most effective international marketing platforms in the field of Vaccine and related biotechnology, which offers a wide range of sponsoring categories for branding and highlighting your company in order to achieve the best publicity.
Expand Your Business - A Cost Effective Sponsorship
  • Get Cost and Time Effective Marketing Exposure and Boost Your Brand Recognition
  • Set Up Stronger Alliances, New Partnerships
  • Showcase Products and Services to a Targeted Prospects of Decision-makers
  • Opportunity to Speak and Announce Recent Company Development
  • Network from 800+ Professionals Offering Opportunities, before, during and after the Conference
Cluster 7: Social & Cultural Activities
Activity 1: Welcome Banquet and Art Performance Activity 2: Industrial Sponsored Cocktail Party
Activity 3: Field Trip to Industry Park/Universities Activity 4: Beijing Impression Tech-Tour
Innova Biosciences
Rapid Novor Inc.
Guangzhou Furi Biological Technology CO., LTD
Mabplex International .Ltd

Desert King International


China Local Time
Days to Go!
Concurrent Congress

Operating Organizations
Official Travel Agency
BIT’s Upcoming Events
Contact Us

Add: East Area, F11, Building 1, Dalian Ascendas IT Park, 1 Hui Xian Yuan, Dalian Hi-tech Industrial Zone, LN 116025, China]
Tel: 0086-411-84799609, Fax: 0086-411-84796897
Copyright © 2015-2016 BIT Congress Inc.